189 related articles for article (PubMed ID: 22511558)
1. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents.
Nordstrom BL; Mines D; Gu Y; Mercaldi C; Aquino P; Harrison MJ
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1357-64. PubMed ID: 22511558
[TBL] [Abstract][Full Text] [Related]
2. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
3. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.
Simard JF; Neovius M; Hagelberg S; Askling J
Arthritis Rheum; 2010 Dec; 62(12):3776-82. PubMed ID: 20827782
[TBL] [Abstract][Full Text] [Related]
4. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.
Wolfe F; Michaud K
Arthritis Rheum; 2007 Sep; 56(9):2886-95. PubMed ID: 17729297
[TBL] [Abstract][Full Text] [Related]
5. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
6. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M;
Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
[TBL] [Abstract][Full Text] [Related]
7. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
8. Occupation and cancer - follow-up of 15 million people in five Nordic countries.
Pukkala E; Martinsen JI; Lynge E; Gunnarsdottir HK; Sparén P; Tryggvadottir L; Weiderpass E; Kjaerheim K
Acta Oncol; 2009; 48(5):646-790. PubMed ID: 19925375
[TBL] [Abstract][Full Text] [Related]
9. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
10. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
11. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
[TBL] [Abstract][Full Text] [Related]
12. The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database.
Gu Y; Nordstrom BL
J Am Acad Dermatol; 2017 Aug; 77(2):293-301.e1. PubMed ID: 28623045
[TBL] [Abstract][Full Text] [Related]
13. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis.
Kok VC; Horng JT; Huang JL; Yeh KW; Gau JJ; Chang CW; Zhuang LZ
BMC Cancer; 2014 Aug; 14():634. PubMed ID: 25174953
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland.
Bolt IB; Cannizzaro E; Seger R; Saurenmann RK
J Rheumatol; 2008 Apr; 35(4):703-6. PubMed ID: 18278829
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study.
Saurenmann RK; Levin AV; Feldman BM; Rose JB; Laxer RM; Schneider R; Silverman ED
Arthritis Rheum; 2007 Feb; 56(2):647-57. PubMed ID: 17265500
[TBL] [Abstract][Full Text] [Related]
16. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
17. Changes in cancer incidence patterns among a northeastern American Indian population: 1955-1969 versus 1990-2004.
Mahoney MC; Va P; Stevens A; Kahn AR; Michalek AM
J Rural Health; 2009; 25(4):378-83. PubMed ID: 19780918
[TBL] [Abstract][Full Text] [Related]
18. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era.
Papadopoulou C; Kostik M; Gonzalez-Fernandez MI; Bohm M; Nieto-Gonzalez JC; Pistorio A; Lanni S; Consolaro A; Martini A; Ravelli A
Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1112-20. PubMed ID: 23335483
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
[TBL] [Abstract][Full Text] [Related]
20. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD;
Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
